Red-Hot Heron Therapeutics Stock Ripe For A Short Squeeze

HRTX stock has doubled in the last year

Managing Editor
Apr 26, 2018 at 2:28 PM
facebook twitter linkedin


Biotech name Heron Therapeutics Inc (NASDAQ:HRTX) once again appeared on Schaeffer's Senior Quantitative Analyst Rocky White's list of stocks that are currently trading near a 52-week high, but also sport a low Schaeffer's Volatility Index (SVI). This combination of stellar price action and relatively inexpensive short-term options could be signaling more tailwinds ahead for the surging drug stock.

Although absolute volume is low, calls are universally popular for HRTX, which sports a 10-day call/put volume ratio of 9.11 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This reading shows that calls have outnumbered puts by a nearly 9-to-1 ratio in the past two weeks.

Furthermore, Heron Therapeutics stock currently sports an SVI of 57%, ranking in the 14th percentile of its annual range. This low reading suggests that near-term options are pricing in relatively low volatility expectations at the moment.

Since 2008, there have been just two other times HRTX stock was flirting with a new high and had an SVI in the bottom 20% of its annual range. After those instances, the shares went on to gain 9.5%, on average, over the next month. A similar pop from current levels would place the equity back above near multi-year highs.

Looking closer, HRTX shares have rapidly climbed since mid-December, with pullbacks contained by their 60-day moving average. The stock, which has doubled in the past year, touched a three-year high of $32.70 on March 19, but was last seen trading 0.5% lower at $30.50.

Heron Stock Chart

Despite this positive price action lately, short sellers have been flocking to the drug stock. Short interest increased by 19% in the two most recent reporting periods to 9.36 million shares, the highest point since early December. This represents more than 21% of HRTX's total available float, and nearly seven days of pent-up buying demand, at the security's average daily trading volume. Should HRTX keep climbing, a short squeeze could be in play. 

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners